Tags

Type your tag names separated by a space and hit enter

Nasal-associated lymphoid tissue immunity and vaccine development.
Adv Otorhinolaryngol. 2011; 72:110-2.AO

Abstract

Nasal vaccination is an effective therapeutic regimen for preventing upper respiratory infectious diseases. In the development of nasal vaccine, an appropriate adjuvant is required. In the present study, we examined the efficacy of fms-like tyrosine kinase receptor-3 ligand (Flt3L) as a mucosal adjuvant. Mice were immunized intranasally with Flt3L and P6 protein of nontypeable Haemophilus influenzae (NTHi), and P6-specific immune responses were examined. In addition, NTHi challenges were performed and the level of NTHi was quantified in nasal washes. Nasal vaccination with P6 and Flt3L induced an increase in the number of dendritic cells in nasal-associated lymphoid tissue. P6-specific nasal wash immunoglobulin (Ig)A and serum IgG titers were elevated significantly after nasal immunization. Enhanced NTHi clearance from the nasopharynx was also observed. These results indicate the potential of Flt3L as an effective mucosal adjuvant and suggest that nasal vaccination with P6 and Flt3L might be an effective regimen for the induction of NTHi-specific protective immunity.

Authors+Show Affiliations

Department of Otolaryngology, Oita University Faculty of Medicine, Hazama-cho, Yufu, Oita, Japan. satoruk@med.oita-u.ac.jpNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

21865705

Citation

Kodama, Satoru, and Masashi Suzuki. "Nasal-associated Lymphoid Tissue Immunity and Vaccine Development." Advances in Oto-rhino-laryngology, vol. 72, 2011, pp. 110-2.
Kodama S, Suzuki M. Nasal-associated lymphoid tissue immunity and vaccine development. Adv Otorhinolaryngol. 2011;72:110-2.
Kodama, S., & Suzuki, M. (2011). Nasal-associated lymphoid tissue immunity and vaccine development. Advances in Oto-rhino-laryngology, 72, 110-2. https://doi.org/10.1159/000324635
Kodama S, Suzuki M. Nasal-associated Lymphoid Tissue Immunity and Vaccine Development. Adv Otorhinolaryngol. 2011;72:110-2. PubMed PMID: 21865705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nasal-associated lymphoid tissue immunity and vaccine development. AU - Kodama,Satoru, AU - Suzuki,Masashi, Y1 - 2011/08/18/ PY - 2011/8/26/entrez PY - 2011/8/26/pubmed PY - 2012/1/18/medline SP - 110 EP - 2 JF - Advances in oto-rhino-laryngology JO - Adv Otorhinolaryngol VL - 72 N2 - Nasal vaccination is an effective therapeutic regimen for preventing upper respiratory infectious diseases. In the development of nasal vaccine, an appropriate adjuvant is required. In the present study, we examined the efficacy of fms-like tyrosine kinase receptor-3 ligand (Flt3L) as a mucosal adjuvant. Mice were immunized intranasally with Flt3L and P6 protein of nontypeable Haemophilus influenzae (NTHi), and P6-specific immune responses were examined. In addition, NTHi challenges were performed and the level of NTHi was quantified in nasal washes. Nasal vaccination with P6 and Flt3L induced an increase in the number of dendritic cells in nasal-associated lymphoid tissue. P6-specific nasal wash immunoglobulin (Ig)A and serum IgG titers were elevated significantly after nasal immunization. Enhanced NTHi clearance from the nasopharynx was also observed. These results indicate the potential of Flt3L as an effective mucosal adjuvant and suggest that nasal vaccination with P6 and Flt3L might be an effective regimen for the induction of NTHi-specific protective immunity. SN - 1662-2847 UR - https://www.unboundmedicine.com/medline/citation/21865705/Nasal_associated_lymphoid_tissue_immunity_and_vaccine_development_ L2 - https://www.karger.com?DOI=10.1159/000324635 DB - PRIME DP - Unbound Medicine ER -